Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Proteomic landscape subtype and clinical prognosis of patients with the cognitive impairment by Japanese encephalitis infection

Fig. 1

Overview of proteomics landscape of CSF in patients with JE. A Workflow of the quantitative proteomic analysis for CSF samples. B Enrolment of patients with JE and collection of clinical data. C Summary of proteomics data analysis procedure for CSF of patients with JE. D Proteomic data sets filtered at different levels for various statistical analyses. D1: 411 proteins were identified in 59 samples (26 patients and 33 controls) at 1% protein level FDR; D2: high confidence unique proteins identified withā€‰ā‰„ā€‰1 unique peptides with peptide FDRā€‰<ā€‰1% that were used for identifying differentially expressed proteins (DEPs) between JE and control; D3: 379 identified proteins with high abundance range (FOTā€‰>ā€‰10ā€‰āˆ’ā€‰5 in at least one case) except potential KRT contaminants; D4: 185 proteins identified in more than one-third of the samples; D5: identified 59 differentially expressed proteins with FOT ratio JE/controlā€‰>ā€‰3 or JE/controlā€‰<ā€‰1/3; D6, Separation CSF sample between JE and Con. E. PCA score plot based on all detected proteins. Patients with JE (red) were apart from the control group (blue)

Back to article page